Quotient Therapeutics Names Susan Keefe as CFO to Advance Somatic Genomics Platform
Key Insights
Quotient Therapeutics (search) appointed Susan Keefe as Chief Financial Officer, bringing 30 years of life sciences finance experience to the somatic genomics company.
Keefe previously served as acting CFO through Flagship Pioneering (search) and held CFO roles at Benson Hill (search) and GreenLight Biosciences (search).
The appointment supports Quotient's mission to develop breakthrough medicines using somatic genomics to identify disease-causal drug targets.
Quotient Therapeutics (search), a Cambridge-based company pioneering somatic genomics for drug discovery, announced the appointment of Susan Keefe as Chief Financial Officer on February 2, 2026. The appointment brings three decades of life sciences finance expertise to support the company's mission of developing breakthrough medicines informed by natural somatic genetic diversity.
Executive Leadership Strengthened
Keefe's appointment follows her role as acting CFO through Flagship Pioneering (search), Quotient's founding organization. "Susan brings a powerful combination of strategic insight, operational rigor and experience building and scaling public and private life science organizations," said Rahul Kakkar, MD, President and Chief Executive Officer of Quotient.
The new CFO expressed enthusiasm for the company's scientific approach, stating, "Somatic genomics has the potential to uncover novel biological insights that inform breakthrough therapies across a broad range of diseases. I look forward to joining the Quotient team and building a solid financial and operational foundation to support the Company's long-term growth and value creation strategy."
Extensive Industry Experience
Keefe's career spans multiple leadership positions across the life sciences sector. Prior to Flagship, she served as Interim CFO of Benson Hill (search) and previously held the CFO position at GreenLight Biosciences (search), where she guided financial strategies for RNA-based solutions in agriculture and human health applications.
Her earlier career included leadership roles at Danforth Advisors (search) and Aushon Biosystems (search), with foundational experience at SeraCare Life Sciences (search), Procter & Gamble, and PwC. Keefe holds an MBA in strategic management, finance, marketing, and entrepreneurship from the University of Chicago Booth School of Business, and a BBA in accounting from the University of Iowa.
Somatic Genomics Innovation
Quotient Therapeutics (search) focuses on leveraging natural somatic genetic diversity present in patients to inform drug development. The company utilizes integrated somatic genomics and computational technologies to gain what it describes as "unbiased, unprecedented resolution into disease-causal drug targets."
This approach enables the design and development of first-in-class therapies, positioning the company to establish a new paradigm in biopharma research and development. Quotient maintains both internal programs and partnered initiatives in its pipeline.
Company Foundation and Growth
Founded by Flagship Pioneering (search) in 2022, Quotient represents the venture creation firm's continued investment in genomics-based therapeutic approaches. The company operates from dual locations in Cambridge, Massachusetts and Cambridge, United Kingdom, reflecting its transatlantic research and development strategy.